What are some of the potential effects of SSRIs on neonates when exposed as teratogens?

The potential effects of selective serotonin reuptake inhibitors (SSRIs) on neonates exposed in utero can include temporary neonatal jitters and irritability. This is particularly relevant as SSRIs can cross the placenta and influence the developing fetus. When a neonate experiences jitters and irritability, it may be indicative of withdrawal from the medication or direct effects of the drug on the central nervous system. These symptoms are generally transient and can be managed with supportive care.

The other options reflect more severe outcomes that are not consistently linked to SSRI exposure. While there have been associations suggested between SSRIs and congenital heart defects or persistent pulmonary hypertension in newborns, the evidence is not conclusive enough to assert them as common teratogenic effects, as they can arise from various factors unrelated to SSRI use. Developmental delays are also more complex and dependent on multiple factors and, while some studies suggest potential links, a direct causative outcome related to SSRIs is not well established. Thus, while SSRIs can have effects on neonates, temporary jitters and irritability represent a more commonly recognized and specifically described phenomenon resulting from in utero exposure.